Details
Stereochemistry | ACHIRAL |
Molecular Formula | Mg.2HO |
Molecular Weight | 58.3197 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[OH-].[OH-].[Mg++]
InChI
InChIKey=VTHJTEIRLNZDEV-UHFFFAOYSA-L
InChI=1S/Mg.2H2O/h;2*1H2/q+2;;/p-2
DescriptionSources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Sources: http://www.internationalcrystal.net/optics_11.htm | https://www.ncbi.nlm.nih.gov/pubmed/27792982 | https://www.ncbi.nlm.nih.gov/pubmed/26952467 | https://www.ncbi.nlm.nih.gov/pubmed/27995243https://www.scbt.com/scbt/product/magnesium-nitrate-hexahydrate-13446-18-9 | https://www.ncbi.nlm.nih.gov/pubmed/18964415 | https://www.ncbi.nlm.nih.gov/pubmed/2843308http://www.db-pharma.com/anglais/49.pdfhttp://www.sciencedirect.com/science/article/pii/004484868990080Xhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020309s028lbl.pdfhttps://hazmap.nlm.nih.gov/category-details?table=copytblagents&id=1640DOI: 10.2903/j.efsa.2008.883http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2013.3444/pdfdoi: 10.1081/SCC-120022479https://www.xymogen.com/assets/imageDisplay.ashx?productID=111&attachmentTypeID=1https://www.drugs.com/ppa/magnesium-chloride.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/15480451 | https://www.scbt.com/scbt/product/magnesium-iodide-10377-58-9https://www.drugs.com/dosage/magnesium-lactate.htmlhttp://dx.doi.org/10.1155/2015/498932 | http://iicbe.org/upload/4152C514072.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9873215 | http://discovery.ucl.ac.uk/1336882/1/1336882.pdf
Struvite, a crystalline substance first identified in the 18th century, is composed of magnesium ammonium
phosphate. Struvite urinary stones are also known as ‘infection stones’, and account for 15%-20% of all urinary stones. Bacterial urease, usually from a Proteus species, is responsible for the chemical changes in urine which result in struvite formation.
CNS Activity
Sources: DOI: 10.1002/0471238961.0218151310010311.a02Vink, R., Mihai Nechifor, M. (2011) 'Magnesium in the Central Nervous System', p.139 Retrieved from https://books.google.ru/books?id=GW0oExaZ7hQChttps://www.drugs.com/mtm/magnesium-lactate.html | https://www.ncbi.nlm.nih.gov/pubmed/27792736 | https://www.ncbi.nlm.nih.gov/pubmed/7669506
Curator's Comment: Magnesium Chloride
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/351265
Curator's Comment: Ulex, a Swedish geologist, is generally credited with introduction of the term struvite in1845
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0001508 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12225296 |
|||
Target ID: GO:0010960 |
|||
Target ID: GO:0033609 |
|||
Target ID: GO:0010960 |
|||
Target ID: P05109 Gene ID: 6279.0 Gene Symbol: S100A8 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8061680 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Preventing | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Diagnostic | ColPrep Kit Approved UseINDICATIONS AND USAGE
ColPrep Kit is indicated for cleansing of the colon as a preparation for colonoscopy in adults Launch Date2016 |
|||
Primary | MAGNESIUM SULFATE Approved UseINDICATIONS AND USAGE
Magnesium Sulfate in Water for Injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. When used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. Launch Date1995 |
|||
Curative | MagMin Approved UseMagnesium aspartate (MagMin) is indicated for patients with documented hypomagnesaemia. |
|||
Curative | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Primary | DELBIASE Approved UseUnknown |
|||
Curative | Magnesium Chloride Approved UseMagnesium Chloride injection is indicated as an electrolyte replenisher in magnesium deficiencies |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Palliative | Magnesium Chloride Approved UseUnknown |
|||
Primary | EPIMAG Approved UseMagnesium citrate is indicated in cases of oxaluria, to prevent recurrence of calcium oxalate kidney stones. |
|||
Primary | EPIMAG Approved UseUsed to relief of occasional constipation (irregularity). |
|||
Curative | Magnesium Citrate Approved UseMagnesium citrate is indicated to supports magnesium nutritional adequacy. |
|||
Curative | Unknown Approved UseMagnesium lactate is a naturally occurring mineral that is needed in the body to support the function of the heart, nervous system, and digestive system. Magnesium lactate is used as a mineral supplement to treat magnesium deficiency. |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of manganese, calcium, magnesium and lithium on the ouabain-induced seizure. | 1977 |
|
Evidence for separate peptide sequences related to the lipolytic and magnesium-accumulating activities of ACTH. Analogy with adrenergic receptors. | 1977 Apr |
|
Characterization of the prolactin receptor in human prostate. | 1983 Nov |
|
Metal: ATP characteristics of insulin- and epidermal growth factor-stimulated phosphorylation in detergent extracts of rat liver plasma membranes. | 1986 Sep |
|
Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. | 1988 Sep 1 |
|
Effect of magnesium diet in gentamicin-induced acute renal failure in rats. | 1989 |
|
[Arrhythmogenic effect of flecainide--treatment with i.v. magnesium]. | 1989 Sep |
|
Role of magnesium in cardiac tachyarrhythmias. | 1990 Jun 19 |
|
Persistent paralysis in critically ill patients after long-term administration of vecuronium. | 1992 Aug 20 |
|
['Cardiac ballet' with and without amiodarone]. | 1993 Jan 13 |
|
Overexpressed protein kinase C-delta and -epsilon subtypes in NIH 3T3 cells exhibit differential subcellular localization and differential regulation of sodium-dependent phosphate uptake. | 1994 Feb 18 |
|
Cocaine-induced cerebrovasospasm and its possible mechanism of action. | 1994 Mar |
|
Differential modulation of alpha 3 beta 2 and alpha 3 beta 4 neuronal nicotinic receptors expressed in Xenopus oocytes by flufenamic acid and niflumic acid. | 1995 Mar |
|
Effects of felbamate on muscarinic and metabotropic-glutamate agonist-mediated responses and magnesium-free or 4-aminopyridine-induced epileptiform activity in guinea pig olfactory cortex neurons in vitro. | 1996 Jun |
|
Familial hypomagnesemia--hypercalciuria and pseudotumor cerebri. | 2001 |
|
Cell-associated magnesium and QT dispersion in hemodialysis patients. | 2003 Jan |
|
Interaction of Tl+ with product complexes of fructose-1,6-bisphosphatase. | 2003 May 2 |
|
Enhancement of endotoxin-induced vascular hyporeactivity to phenylephrine in the thoracic aortas of Mg-deficient rats ex vivo. | 2003 Oct 10 |
|
Ablation of calcitonin/calcitonin gene-related peptide-alpha impairs fetal magnesium but not calcium homeostasis. | 2004 Aug |
|
Use of ibutilide in cardioversion of patients with atrial fibrillation or atrial flutter treated with class IC agents. | 2004 Aug 18 |
|
Low maternal dietary intakes of iron, magnesium, and niacin are associated with spina bifida in the offspring. | 2004 Jun |
|
Magnesium influence on morphine--induced pharmacodependence in rats. | 2004 Mar |
|
In vitro application of endotoxin to thoracic aortas from magnesium-deficient rats enhances vascular hyporeactivity to phenylephrine. | 2004 Oct |
|
Prevention of succinylcholine-induced fasciculation and myalgia: a meta-analysis of randomized trials. | 2005 Oct |
|
Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. | 2005 Oct |
|
Conformational changes in sarcoplasmic reticulum Ca(2+)-ATPase mutants: effect of mutations either at Ca(2+)-binding site II or at tryptophan 552 in the cytosolic domain. | 2006 Apr 25 |
|
Structure of pyrimidine 5'-nucleotidase type 1. Insight into mechanism of action and inhibition during lead poisoning. | 2006 Jul 21 |
|
Activation and enzymatic characterization of recombinant human kallikrein 8. | 2006 Jun |
|
Evidence for a two-step mechanism involved in the formation of covalent HC x TSG-6 complexes. | 2006 Jun 20 |
|
Multivariate analysis of the selected metals in the hair of cerebral palsy patients versus controls. | 2006 Summer |
|
Magnesium attenuates isoproterenol-induced acute cardiac dysfunction and beta-adrenergic desensitization. | 2007 Mar |
|
Cisplatin-induced hypomagnesemia and cardiac dysrhythmia. | 2007 Nov |
|
The relation of magnesium and calcium intakes and a genetic polymorphism in the magnesium transporter to colorectal neoplasia risk. | 2007 Sep |
|
Interactions between magnesium and psychotropic drugs. | 2008 Jun |
|
Cocaine use disorders and serum magnesium profile. | 2009 |
|
Differential binding of inorganic particles to MARCO. | 2009 Jan |
|
AZT-induced oxidative cardiovascular toxicity: attenuation by Mg-supplementation. | 2009 Jun |
|
The loop connecting metal-binding domains 3 and 4 of ATP7B is a target of a kinase-mediated phosphorylation. | 2009 Jun 23 |
|
Hair tissue mineral analysis and metabolic syndrome. | 2009 Sep |
|
Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). | 2010 Apr 13 |
|
Involvement of transient receptor potential melastatin-related 7 (TRPM7) channels in cadmium uptake and cytotoxicity in MC3T3-E1 osteoblasts. | 2010 Dec 15 |
|
Carcinogenic heavy metals replace Ca2+ for DNA binding and annealing activities of mono-ubiquitinated annexin A1 homodimer. | 2010 Oct 1 |
|
Metals affect the structure and activity of human plasminogen activator inhibitor-1. I. Modulation of stability and protease inhibition. | 2011 Feb |
|
Mechanically enforced bond dissociation reports synergistic influence of Mn2+ and Mg2+ on the interaction between integrin α7β1 and invasin. | 2011 Jul-Aug |
|
Hypoxia induces an increase in intracellular magnesium via transient receptor potential melastatin 7 (TRPM7) channels in rat hippocampal neurons in vitro. | 2011 Jun 10 |
|
NADH fluorescence lifetime analysis of the effect of magnesium ions on ALDH2. | 2011 May 30 |
|
Increased zinc and manganese in parallel with neurodegeneration, synaptic protein changes and activation of Akt/GSK3 signaling in ovine CLN6 neuronal ceroid lipofuscinosis. | 2013 |
|
Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1. | 2013 Feb 25 |
|
Altered biometal homeostasis is associated with CLN6 mRNA loss in mouse neuronal ceroid lipofuscinosis. | 2013 Jun 15 |
|
Assessment of infantile mineral imbalances in autism spectrum disorders (ASDs). | 2013 Nov 11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27995243
Curator's Comment: Rats: MgF2 dissolved in acetic acid (Mg=0.08 mM, F=0.084 mM) was delivered in the aerosol form
https://www.ncbi.nlm.nih.gov/pubmed/20647692
Murine osteomyelitis model: medical pure titanium plates in size of 10 mm × 10 mm × 1 mm
were used for the deposition of Magnesium Fluoride (MgF2) film.
Route of Administration:
Topical
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QG04BX01
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
JECFA EVALUATION |
INS-528
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
WHO-ATC |
G04BX01
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
DSLD |
3079 (Number of products:35)
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
WHO-ATC |
A02AA04
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
CFR |
21 CFR 184.1428
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
NCI_THESAURUS |
C29697
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
WHO-VATC |
QA02AA04
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-528
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
215-274-9
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
DTXSID4049662
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
MAGNESIUM HYDROXIDE
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200718
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
NBZ3QY004S
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
1309-42-8
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
C29262
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
1317-43-7
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
ALTERNATIVE | |||
|
4244
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
14791
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
35110
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
MAGNESIUM HYDROXIDE
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | Description: A white, fine, amorphous powder; odourless. Solubility: Practically insoluble in water and ethanol (~750 g/l) TS; soluble in dilute acids. Category: Antacid. Storage: Magnesium hydroxide should be kept in a tightly closed container. Definition: Magnesium hydroxide contains not less than 95.0% and not more than 100.5% of Mg(OH)2, calculated with referenceto the dried substance. | ||
|
659
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
NBZ3QY004S
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
m7004
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB09104
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
215-170-3
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
BRUCITE
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
6581
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | RxNorm | ||
|
1374260
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
6637
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
Magnesium Hydroxide
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
D008276
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
100000090104
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY | |||
|
SUB14429MIG
Created by
admin on Fri Dec 15 15:38:44 GMT 2023 , Edited by admin on Fri Dec 15 15:38:44 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
ACTIVE MOIETY
SUBSTANCE RECORD